

RESEARCH

Open Access



Sex-specific hypothalamic neuropathology and glucose metabolism in an amyloidosis transgenic mouse model of Alzheimer's disease

Guibo Qi^{1†}, Han Tang^{1†}, Pifang Gong¹, Yitong Liu¹, Chenzhao He¹, Jianian Hu¹, Siying Kang¹, Liang Chen^{1*} and Song Qin^{1,2*} 

Abstract

Background Amyloid toxicity and glucose metabolic disorders are key pathological features during the progression of Alzheimer's disease (AD). While the hypothalamus plays a crucial role in regulating systemic energy balance, the distribution of amyloid plaques in the preoptic, anterior, tuberal, and mammillary regions of the hypothalamus in AD mice, particularly across both sexes, remains largely unclear. Our ongoing research aims to explore hypothalamic neuropathology and glucose metabolic disturbances in a well-described APP/PS1 mouse model of AD.

Results Immunocytochemical staining revealed that Old-AD-Female mice exhibited a greater hypothalamic Amyloid β (A β) burden than their Old-AD-Male counterparts, with the mammillary bodies showing the most severe accumulation. Analysis of ionized calcium binding adaptor molecule 1 (IBA1) immunoreactivity and *Iba1* mRNA indicated differential microgliosis based on sex, while tanycytic territory and ZO-1 tight junction protein expression remained stable in AD mice. Moreover, sex-specific peripheral glucose metabolic parameters (random and fasting blood glucose) seemed to be exacerbated by age. Old AD mice of both sexes exhibited limited hypothalamic activation (c-Fos+ cells) in response to blood glucose fluctuations. Hypothalamic *Glut 1* expression decreased in young but increased in old female AD mice compared with age-matched male AD mice. Pearson correlation analysis further supported a negative correlation between hypothalamic A β load and random blood glucose in old AD groups of both genders, shedding light on the mechanisms underlying this amyloidosis mouse model.

Conclusion Aged APP/PS1 mice exhibit sex-specific hypothalamic neuropathology and differential glucose metabolism, highlighting distinct pathological mechanisms within each gender.

Keywords Alzheimer's disease, Amyloid plaque, Glucose metabolism, Gliosis, Hypothalamus, Neuropathology

[†]Guibo Qi and Han Tang have contribute equally to the article.

*Correspondence:

Liang Chen
liangchen@fudan.edu.cn
Song Qin
sqin@fudan.edu.cn

¹ Department of Anatomy, Histology and Embryology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

² State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China

Introduction

Alzheimer's disease (AD), an aging-related neurodegenerative disorder, is clinically characterized by memory loss and cognitive impairment [1, 2]. Its major hallmarks include amyloid β (A β) deposits and neurofibrillary tangles, leading to neuronal dysfunction and reactive gliosis [3–5]. A β plaques typically originate from pyramid neurons in the cortex and spread to other brain regions [6]. The hypothalamus, situated at the crossroads of peripheral, environmental, and neural inputs, integrates sensory information to regulate various physiological functions



and behaviors [7]. Despite its complex structure comprising numerous neuron categories and nuclei, how each of the hypothalamic regions—preoptic, anterior, tuberal, and mammillary—experiences A β deposition remains largely unknown. Epidemiologically, approximately two-thirds of AD patients are women, indicating potential sex-specific differences in disease risk factors [8]. However, investigations into the sex-specific neuropathological variations in both human AD patients and amyloidosis transgenic mouse models remain limited.

Accumulating evidence suggests the role of hypothalamic glial populations in the AD brain [9, 10]. Microglia, expressing ionized calcium binding adaptor molecule (IBA1), drive the accumulation of A β plaques and cognitive deficits through a glycolysis/H4K12la/PKM2 (pyruvate kinase M2) positive feedback loop in AD mice [11]. Astrocytes undergo functional transformation into reactive astrogliosis, with the astrocytic α 7 nicotinic acetylcholine receptor (α 7nAChR) emerging as a potential biomarker candidate [12]. To date, the morphological and functional changes these cells undergo in the AD hypothalamus remain unclear. Indeed, tanycytes are radial glial-like ependymal cells located in the ventral part of the third ventricle (3 V), exhibiting intrinsic heterogeneity with α 1, α 2, β 1, and β 2 subpopulations [13]. Physiologically, tanycytes lining the ventral 3 V are connected at their apices by functional tight junctions [14] and participate in the remodeling of blood–hypothalamus barrier by expressing vascular endothelial growth factor-A [15]. These cells contribute to maintain energy balance and fat metabolism by sensing signals such as leptin and insulin, as well as circulating nutrients like glucose [16–18]. Recent lineage tracing studies suggest that tanycytes contribute to tissue repair under neural injury and may possess tumorigenic potential [19], indicating their response to pathological stimulation.

Another distinct feature of AD is disturbances in glucose and energy metabolism [20, 21]. It has been proposed that metabolic changes specific to certain brain regions precede the development of amyloid pathology and cognitive decline, with the hypothalamus undergoing significant metabolic alterations [22]. However, the relationship between systemic glucose levels and amyloid accumulation in aged AD mice of both sexes remains poorly understood. Robinson LS et al. provided evidence for sex-dependent effects of AD pathology on energy and glucose regulation [23], potentially linked to inflammation in the hypothalamus. Other studies have also reported sex differences in hypothalamic responses to metabolic challenges [24]. High-fat diets resulted in the greatest weight gain, adiposity, and glucose intolerance in 3xTg-AD females, accompanied by a significant increase in hypothalamic expression of glial fibrillary

acidic protein (GFAP) and interleukin-1 β (IL-1 β) [25]. Interestingly, this effect was not observed in AD males [25], indicating a sexual dimorphic response to metabolic challenges.

Genetically, Rasse, R and colleagues established a transgenic AD mouse model known as APP/PS1 mice, which develop cerebral amyloidosis starting at 6–8 weeks of age [26]. While we previously traced reactive astrogliosis in the cortex of this AD mouse model and identified transcriptional alterations [27], the presence of amyloidosis in the hypothalamus has not been explored, nor has the metabolic profile of this AD mouse model been examined in a sex-specific manner.

The aim of this study is to investigate A β deposits in different regions of the hypothalamus in thoroughly characterized AD mice, focusing on both early and late pathological stages. We conducted immunocytochemical staining, mRNA measurements, and metabolic analyses on both young and old male and female AD mice. Additionally, we explored the relationship between hypothalamic A β pathology and systemic glucose metabolism, offering further insights into this amyloidosis mouse model.

Materials and methods

Animal care

Wild-type (WT) C57BL/6 J mice were purchased from the Shanghai SLAC Laboratory (Shanghai, China). AD mice (Thy1–APPKM670/671NL, Thy1–PS1 L166P) harbor both the amyloid precursor protein (APP) with the KM670/671NL (Swedish) mutation and presenilin 1 (PS1) with the L166P mutation on a C57BL/6 J genetic background [26]. The mice were housed in groups of 4–6 per cage, provided with ad libitum access to food and water, and maintained under a 12-h light/dark cycle. Both young (3–4 months old) and old (14–15 months old) male and female mice were included in this study. All animal procedures were conducted in compliance with the guidelines and ethical regulations established by the Animal Care and Use Committee of Shanghai Medical College of Fudan University.

Brain tissue preparation

Mice were anesthetized with pentobarbital sodium and xylazine, then subjected to transcatheterial perfusion with 1X ice-cold phosphate-buffered saline (PBS), followed by perfusion with 4% paraformaldehyde solution in PBS. Subsequently, the brains were carefully dissected and postfixed in 4% paraformaldehyde for 24–48 h at 4 °C. The fixed brains were then transferred to 30% sucrose solution in PBS until they sank. After sinking, the brains were coronally sectioned to a thickness of 40 μ m using a cryostat (Leica Microsystems) and stored in an

anti-freeze solution at -20°C until immunohistochemical analysis. To perform c-Fos analysis, mice received an intraperitoneal injection (i.p.) of glucose solution (2 g/kg body weight) 2 h before scarification following the methods above.

Immunocytochemistry

Brain sections were washed with 1X PBS and permeabilized with 0.3% Triton X-100 for 30 min at room temperature. Subsequently, the brain sections were blocked with 5% bovine serum albumin for 1 h at 4°C . Following overnight incubation with primary antibodies at 4°C , sections were washed and then incubated for 2 h with corresponding Alexa Fluor-conjugated secondary antibodies. Finally, the nuclei in each section were counterstained with Hoechst 33,258 (1 $\mu\text{g}/\text{ml}$). Antibodies used were as follows: 6E10 (1:500, AB_2564765, BioLegend), $\text{A}\beta 1\text{-}42$ (1:500, ab224275, Abcam), GFAP (1:800, G3893, Thermo Scientific), IBA1 (1:1000, 019-19741, Waco), HuCD (1:1000, A-21271, Thermo Scientific); Vimentin (1:1500, AB_11212377, Merck & Millipore), ZO-1 (1:500, AB_2533147, Invitrogen), c-Fos (1:250, AB_2632380, PhosphoSolutions). Alexa Fluor 488-, 555-, or 647-conjugated corresponding secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA).

Image acquisition and analysis

All brain sections (at least 3 slices per animal) were imaged directly using a fluorescent microscope (EVOS M700 Color Imaging Systems). Additionally, a Leica SP8 microscope (Leica F1300439) was employed to further validate the results. Laser and scanning settings for images within each experiment were kept consistent for comparison between groups. Semi-quantification analysis was conducted by a blinded researcher using ImageJ software (NIH, Bethesda, MD). For amyloid load and IBA1% area, the color threshold tool in ImageJ was adjusted to label immunoreactive signaling while excluding background staining within the region of interest (ROI). The big warp plugin in ImageJ was utilized to merge brain atlas and acquired images for the counting of HuCD+cells. Following precise division, automatic cell counting was performed in various brain regions, including the anterior commissure (AC), medial preoptic nucleus (MPO), lateral preoptic nucleus (LPO), paraventricular nucleus (PVN), anterior hypothalamic nucleus (AHC), suprachiasmatic nucleus (SCN), supraoptic nucleus (SON), lateral hypothalamus (LH), dorsal medial nucleus (DMH), ventral medial nucleus (VMH), arcuate nucleus (ARH), tuberal nucleus (TuN), posterior hypothalamic nucleus (PH), supramammillary nucleus (SuM), and mammillary bodies (MM). Quantification of c-Fos

immunoreactive cells was performed in feed-regulating nuclei, including DMH, VMN, ARH, TuN, and LH. For Sholl analysis, z-stack confocal images were captured at a resolution of 1024×1024 pixels. Photomontages were created with a step of 1 μm using $\times 40$ magnification (between 6 and 10 frames per image). The number of intersections was calculated, starting with a radius of 10 pixels and subsequent shells set at 5 pixels per step. For the ratio of tanycytic layer to the third ventricular surface, the length of the tanycytic layer was reported to the total length of the ventricle. The tanycytic layer was defined as the distance from the bottom of the 3 V to the last tanycyte detected in the dorsal 3 V. The third ventricular surface was defined as the distance from the bottom of the 3 V to the top, measured using Hoechst staining.

Metabolic study and food intake measurement

Blood samples were collected from the tail vein. Random blood glucose (RBG) was measured repeatedly in all WT and AD mice across both young and old groups. Fasting blood glucose (FBG) measurement was performed after overnight fasting. RBG and FBG levels of each animal were the average result of at least three independent measurements. In intraperitoneal glucose tolerance test (IPGTT), each mouse received an i.p. injection of glucose (2 g/kg body weight) after overnight fasting, and blood glucose levels were measured 0, 15, 30, 60, 90, and 120 min after i.p. injection. Subcutaneous fat mass was measured to indicate the wet weight of abdominal fat pad. Before actual food intake and rebound feeding measurements, mice were acclimatized to food hoppers in the cage at least 14 days. Actual food intake was measured continuously for 6 h: the difference between the pre-weighed and the remaining food was reported to 6 h. Fasting for 16 h minimizes the effects of systemic compensation including liver glycogenolysis. After a 16-h overnight fasting, ad libitum food intake was measured 1 h and 2 h after the light cycle started at 7:00–7:30.

RNA isolation and RT-qPCR

As previously reported [28], total RNA was extracted from isolated hypothalamus tissues using TRIzol reagent. Subsequently, total RNA, along with random primers, was utilized to synthesize cDNA using the SuperScript III kit (Takara). We employed the TB Green system (Takara) for real-time quantitative PCR (RT-qPCR) analysis, performed with a 96-well ABI thermocycler (Applied Biosystems). Melting curves of each well were examined to confirm the amplification of a single product. Relative gene expression levels were quantified using the cycle threshold (Ct) method. The following primers were used: *Tnf-a* (forward: GGTGCCTATGTCCTCAGCCTCTT; reverse: GCCATAGA ACTGATGAGAGGGAG); *Ikbk*

(forward: TCTTCGGAGTCAGAGGGAACAG; reverse: TCCTGGAGTTCTCCGAGCAATG); *Iba1* (forward: TCTGCCGTCCAACTTGAAGCC; reverse: CTCTTCAGCTCTAGGTGGGTCT); *Gfap* (forward: CACCTA CAGGAAATTGCTGGAGG; reverse: CCACGATGT TCCTCTTGAGGTG); *Glut1* (forward: GCTTCTCCA ACTGGACCTCAAAC; reverse: ACGAGGAGCACC GTGAAGATGA); *Glut3* (forward: CCGCTTCTCATC TCCATTGTCC; reverse: CCTGCTCCAATCGTGGCA TAGA); *Gapdh* (forward: CCTACCCCAATGTATCC GTT; reverse: TAGCCCAGGATGCCCTTTAGT).

Statistics

All statistical analyses were conducted using GraphPad Prism software (version 8.2, GraphPad Software, La Jolla, CA, USA). Prior to further comparison, normality and lognormality tests were performed to ensure data normality. Data are expressed as mean \pm standard error of the mean (SEM). Data from two groups were analyzed with a two-tailed unpaired Student's t-test. Data of multiple groups were analyzed with one-way analysis of variance (ANOVA) followed by Turkey's multiple comparison post hoc test. Two-way ANOVA followed by Bonferroni's multiple comparison post hoc test was used to compare genotypes and genders over different gender groups. Pearson correlation analysis was performed using RStudio software (version: 2023.12.0+369) and visualized using the corrplot package. Significance levels were denoted on the graphs as follows: *, $0.01 \leq P < 0.05$; **, $0.001 \leq P < 0.01$; ***, $0.0001 \leq P < 0.001$.

Results

Sex-specific amyloid deposition with subregional heterogeneity in the hypothalamus of AD mice

To identify the A β burden in the hypothalamus, we initially segmented it into preoptic, anterior, tuberal, and mammillary regions, each comprising various nuclei (Fig. 1A). Subsequently, we performed co-staining of brain sections from Old-WT-Male, Old-WT-Female, Old-AD-Male, and Old-AD-Female mice using 6E10 and A β_{1-42} antibodies. Across all four regions, A β load was significantly higher in Old-AD-Female mice compared to

Old-WT-Female mice (preoptic region: 6E10 $p=0.0008$, A β_{1-42} $p < 0.0007$; anterior region: 6E10 $p=0.0086$, A β_{1-42} $p=0.0070$; tuberal region: 6E10 $p < 0.0001$, A β_{1-42} $p=0.0014$; mammillary region: 6E10 $p=0.0004$, A β_{1-42} $p < 0.0001$) (Fig. 1B, C). In contrast, we did not observe obvious amyloid plaques in the hypothalamus of Old-AD-Male mice, except in the mammillary region (6E10 load: $p=0.3292$, A β_{1-42} load: $p=0.2328$). Interestingly, Old-AD-Female mice exhibited significantly higher 6E10+ and A β_{1-42} +load compared to Old-AD-Male mice (preoptic region: 6E10 $p=0.0048$, A β_{1-42} $p=0.0035$; anterior region: 6E10 $p=0.0667$, A β_{1-42} $p=0.0952$; tuberal region: 6E10 $p=0.0001$, A β_{1-42} $p=0.0100$; mammillary region: 6E10 $p=0.0882$, A β_{1-42} $p=0.0069$) (Fig. 1B, C). To further confirm sex-specific amyloidosis, we applied confocal microscopy and detected more plaques in fornix and mammillary bodies of Old-AD-Female than Old-AD-Male mice (Fig. S1 A, B). However, no amyloid deposits were observed in the suprachiasmatic nucleus of the old groups (Fig. S1C).

Next, we examined whether the young group exhibited A β deposits in hypothalamic subdivisions. Images revealed that a few A β plaques were present in the mammillary region of both Young-AD-Male and Young-AD-Female mice (Fig. S2). Taken together, in this AD mouse line, the rostral-to-caudal hypothalamic microenvironment was differentially disrupted by senile plaques, with the mammillary region suffering from the most severe and earliest amyloid depositions. Old-AD-Female mice exhibited a heavier A β burden than their male counterparts, indicating sex-dependent amyloid pathology.

Intact hypothalamic neuronal populations and NF-kb signaling pathways in AD mice

Sexual dimorphism of neuronal loss has been reported in the subiculum [29]. However, global neocortical neuron loss was not apparent until 8 months of age in the AD mouse model we used [26]. Given the presence of A β deposits along the rostral-to-caudal axis of the hypothalamus, it is intriguing to identify nucleus-specific neuronal populations. Therefore, we evaluated diverse hypothalamic nuclei (MPO, PVN, AHC, SCN, DMH,

(See figure on next page.)

Fig. 1 Comparative analysis of amyloid plaques in hypothalamic subdivisions. **A** Nucleus staining (Hoechst, blue) reveals four regions of hypothalamus in mice, including preoptic, anterior, tuberal, and mammillary regions. Nuclei indicated by dashed circles are labeled on the other side of the same slice. AC anterior commissure, MPO medial preoptic nucleus, LPO lateral preoptic nucleus, PVN paraventricular nucleus, AHC anterior hypothalamic nucleus, SCN suprachiasmatic nucleus, SON supraoptic nucleus, LH lateral hypothalamus, DMH dorsomedial nucleus, VMH ventralmedial nucleus, ARH arcuate nucleus, TuN tuberal nucleus PH posterior hypothalamic nucleus, SuM supramammillary nucleus, MM mammillary bodies. Scale bar: 1 mm. **B** Representative images of 6E10 and A β_{1-42} co-staining in hypothalamic preoptic and anterior regions of Old-AD-Male and Old-AD-Female subsets. Corresponding quantification of 6E10+ and A β_{1-42} +load ($n=5-10$). **C** Representative images of 6E10 and A β_{1-42} co-staining in hypothalamic tuberal and mammillary regions of Old-AD-Male and Old-AD-Female subsets. Corresponding quantification of 6E10+ and A β_{1-42} +load ($n=5-10$). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$, two-way ANOVA followed by Bonferroni's multiple comparison




Fig. 1 (See legend on previous page.)

VMH, ARH, TuN, LH, PH, SuM, MM) in this AD mouse model using HuCD staining. However, no significant differences were observed in neuronal density among the 8 subsets, regardless of genotypes and genders (Fig. S3A, D). Functionally, we measured *Tnf- α* (a classic inflammatory factor) mRNA expression and found consistent levels of overall hypothalamic neuroinflammation (Old-AD-Male vs Old-WT-Male: $p=0.7009$; Old-AD-Female vs Old-WT-Female: $p=0.1284$) (Fig. S3B, E). Additionally, an inhibitor of nuclear factor kappa-B kinase subunit beta (*Ikk β*), was comparable among all subsets of the young and old group. Thus, neurons in various hypothalamic nuclei tend to remain intact, and the level of overall hypothalamic neuroinflammation is largely unaffected in both the early and late stages of this AD mouse line.

Differential microgliosis based on sex in the MM of AD mice

Microglia, generally considered as a sensitive inflammatory predictor, have recently been supposed as AD culprits [30]. In the old AD groups, we observed significantly larger IBA1% area in the MPO (Old-AD-Male vs Old-WT-Male: $p=0.0133$; Old-AD-Female vs Old-WT-Female: $p=0.0319$), LH, (Old-AD-Male vs Old-WT-Male: $p=0.0491$; Old-AD-Female vs Old-WT-Female: $p=0.0480$) and MM (Old-AD-Male vs Old-WT-Male: $p=0.0450$; Old-AD-Female vs Old-WT-Female: $p<0.0001$) (Fig. 2A, B). In the MM, where A β plaques are produced robustly within the hypothalamus, microgliosis was more pronounced in Old-AD-Female mice than in Old-AD-Male subsets ($p=0.0023$). Additionally, Sholl analysis revealed more interactions in both Old-AD-Male and Old-AD-Female mice compared to WT counterparts (Fig. 2C). Similarly, *Iba1* mRNA levels in the entire hypothalamus were consistent with protein expressions (Old-AD-Male vs Old-WT-Male: $p=0.6798$; Old-AD-Female vs Old-WT-Female: $p=0.0482$) (Fig. 2D). These results suggest differential microgliosis based on sex in aged AD mice.

In the young groups, a larger IBA1% area was only found in the MM (where A β plaques are produced earliest) of Young-AD-Female compared with Young-WT-Female ($p=0.0479$) (Fig. S4A, B). No differences were observed in *Iba1* mRNA expression (Fig. S4C). Furthermore, we investigated astrocytic reaction in the MM to confirm gliosis. In the young group, GFAP antibody immunostaining were undetectable, and *Gfap* mRNA expression was similar among the 4 subsets (Fig. S4D, E). In contrast, both Old-AD-Male and Old-AD-Female mice displayed GFAP immunoreactivity in the MM (Fig. S4F). Additionally, *Gfap* mRNA was increased in Old-AD-Female compared to Old-AD-Male mice ($p=0.0167$) (Fig. S4G).

Stable tanycytic territory and honeycombed tight junction protein ZO-1 in AD mice


There is growing evidence indicating that tanycytes play a role in maintaining brain glucose sensing [31]. Due to their peculiar distribution, tanycytes are conventionally divided into four subpopulations based on their dorsal-ventral position [32]. In our study, we initially divided the tuberal region of the hypothalamus (from bregma -1.3 to -2.5 mm) into four zones: zone 1 (from bregma -1.3 to -1.6 mm), zone 2 (from bregma -1.6 to -1.8 mm), zone 3 (from bregma -1.8 to -2.1 mm), and zone 4 (from bregma -2.1 to -2.5 mm) along the antero-posterior axis (Fig. 3A, B). Tanycytic territory was assessed by the ratio of the tanycytic layer to the surface of the 3 V vimentin-positive (vimentin+) tanycytes (Fig. 3C). Across zones 1 to 4, tanycytic territory remained consistent among the four subsets of the old group (Fig. 3D, E). We then examined tight junction proteins, particularly ZO-1, which are crucial for the structure of blood-cerebrospinal fluid barriers and prevent the diffusion of blood-borne molecules into the cerebrospinal fluid [33]. In zone 3 of Old-AD-Male and Old-AD-Female mice, tanycytes exhibited a continuous ZO-1+honeycomb pattern at the apex and predominantly lined the 3 V wall adjacent to ME (Fig. 3D). Similarly, stable tanycytic territory and ZO-1+honeycomb patterns were also observed in the young group (Fig. S5). These results suggest that tanycytic territory and ZO-1 tight junction proteins are not susceptible to AD pathology in this mouse model.

Sex differences of systemic glucose metabolism in young and old AD mice


To explore the toxicity induced by cerebral A β plaques and its association with various peripheral and central abnormalities [34], we assessed multiple parameters of glucose metabolism in both young and old groups following the outlined workflow (Fig. 4A). In the young group, the value of FBG (a challenged glucose metabolic parameter) was significantly reduced in Young-AD-Female compared to Young-AD-Male mice ($p=0.0036$), and showed a decreasing trend in Young-WT-Female compared to Young-WT-Male mice ($p=0.0774$) (Fig. 4C). Intriguingly, the FBG of Young-AD-Female mice was similar to that of Young-WT-Female mice ($p=0.8721$). Additionally, no significant differences were observed among the four young subsets in the values of RBG, GTT, subcutaneous fat mass, actual food intake, or rebound feeding (Fig. 4B, D, E, F, G). To sum up, the glucose metabolic profile of young AD mice differed significantly between the two genders.

In the old group, RBG ($p<0.0001$) and FBG ($p<0.0001$) were significantly lower in Old-AD-Female mice compared to Old-AD-Male mice (Fig. 4H, I). Unexpectedly,


A



B



C



D




Fig. 2 Microgliosis in various hypothalamic nuclei. **A** Representative image of IBA1 staining in mammillary bodies. Areas indicated by square are further amplified below via confocal. **B** Percentage of ROI occupied by IBA1-positive area (n=6). **C** Binary picture of a single microglia against concentric circles and a heat map based on the same microglia. Number of intersections in Sholl analysis (n=8). *: WT-male vs AD-male; #: WT-female vs AD-female. *p < 0.05, #p < 0.05, ##p < 0.01. **d** Relative mRNA expression of IBA1. *p < 0.05, two-way ANOVA followed by Bonferroni's multiple comparison

RBG ($p=0.0011$) and FBG ($p=0.0020$) were also significantly lower in Old-WT-Female compared to Old-WT-Male mice, while these statistical differences did not exist between Young-WT-Female and Young-WT-Male mice (Fig. 4B). In either Old-AD-Male or Old-AD-Female mice groups, both RBG and FBG are similar to WT control groups (Fig. 4G, H). Glucose tolerance and all feeding behavioral parameters of Old-AD-Female mice were comparable to those of Old-AD-Male mice (Fig. 4J, K, L, M). These findings suggest that the level of systemic blood glucose differs in a sex-specific manner, indicating that age-related glucose metabolism seems to be independent of AD genotype.

Low activation of feed-regulating hypothalamic nucleus in aged AD mice

We next traced the central response to acute glycemia upregulation by measuring cellular *c-Fos* expression in hypothalamic nuclei involved in regulating feeding and glucose metabolism. Two hours after intraperitoneal injection of a glucose solution (2 g/kg), we found that the numbers of *c-Fos*+cells in the DMH, VMH, ARH, TuN, and LH were identical among the young groups (Young-WT-Male, Young-WT-Female, Young-AD-Male, Young-AD-Female mice) (Fig. 5A). Exceptionally, the number of *c-Fos*+cells in the DMH ($p=0.0130$) and ARH ($p=0.0363$) were slightly higher in Young-WT-Female mice compared to Young-WT-Male mice (Fig. 5A).

In the old group, we found significantly fewer *c-Fos*+cells in the DMH ($p=0.0035$), VMH ($p=0.0490$), TuN ($p=0.0390$), and LH ($p=0.0058$) of Old-AD-Male mice compared to Old-WT-Male mice (Fig. 5B). Similarly, a small number of *c-Fos*+cells were observed in Old-AD-Female mice, although they did not reach a significant level compared with WT controls (Fig. 5B). Additionally, *c-Fos*+cells in the DMH of Old-WT-Female mice were slightly decreased compared to Old-WT-Male mice ($p=0.0150$) (Fig. 5B). Overall, both Old-AD-Male and Old-AD-Female mice exhibited limited hypothalamic activation in response to blood glucose fluctuations.

Systemic glucose metabolism was negatively correlated with hypothalamic amyloid pathology in aged AD mice of both sexes

The glucose transporter transporter 1 (GLUT1) at the blood–brain barrier (BBB) mediates glucose transport into the brain, and GLUT1 deficiency exacerbates AD-related cerebrovascular degeneration in the cortex and hippocampus [35]. Neurons primarily obtain extracellular glucose as fuel, mainly relying on glucose transporter 3 (GLUT3) [36]. We observed slightly increased hypothalamic *Glut1* mRNA levels in Young-AD-Male compared to either Young-WT-Male ($p=0.0397$) or Young-AD-Female mice ($p=0.0470$) (Fig. 6A). *Glut3* mRNA expression was similar among the four subsets of the young group (Fig. 6B). Surprisingly, in the old group, hypothalamic *Glut1* mRNA levels were significantly higher in Old-AD-Female compared to either Old-WT-Female ($p=0.0089$) or Old-AD-Male mice ($p=0.0269$). There was no statistical difference in *Glut3* mRNA expression between Old-AD-Male and Old-AD-Female ($p=0.5357$).

Finally, we investigated whether hypothalamic amyloid pathology was associated with systemic glucose metabolic parameters in Old-AD-Male and Old-AD-Female mice. Pearson analysis showed that in the hypothalamus of Old-AD-Male mice, $A\beta_{1-42}$ load was negatively correlated with RBG ($r=-0.93$, $p<0.01$). Both 6E10 load ($r=-0.86$, $p<0.01$) and $A\beta_{1-42}$ load ($r=-0.66$, $p<0.05$) in Old-AD-Female mice were strongly and negatively correlated with RBG. Additionally, the percentage of IBA1-covered areas in the total hypothalamus of Old-AD-Male and Old-AD-Female mice was not statistically associated with $A\beta$ deposition ($A\beta_{1-42}$ load or 6E10 load).

Discussion

This study reveals an uneven distribution of senile plaques in the rostral-to-caudal hypothalamus of AD mice, with the earliest and densest accumulation observed in the MM region. Old-AD-Female mice exhibited a higher $A\beta$ burden and gliosis compared to Old-AD-Male mice. In contrast, tanycytic territories remained stable, and the honeycombed patterns of ZO-1 were retained in the old AD mice group. Sex-specific

(See figure on next page.)

Fig. 3 Tanycytes lining the lateral and ventral wall of the third ventricle (3 V). **A** Classical distribution of tanycytes in the tuberal region of the hypothalamus (adapted with the permission of Prof. Fanny Langlet). **B** The sagittal schematic showing zone 1 (from bregma -1.3 to -1.6 mm), zone 2 (from bregma -1.6 to -1.8 mm), zone 3 (from bregma -1.8 to -2.1 mm) and zone 4 (from bregma -2.1 to -2.5 mm) along the anteroposterior axis. **C** Immunohistochemistry for the intermediate filament vimentin (white) showing all subtypes of tanycytes and ependymocytes populating the 3 V wall of mice. The tanycytic layer (distance from the 3 V bottom to the top tanycytes) and the 3 V surface (distance from the bottom to the top of 3 V) are delineated. Scale bar, 300 μ m. **D** Vimentin-positive tanycytes distribute from zone 1 to zone 4 in the old group. Pattern of tight junction protein ZO-1 (red) is honeycombed in bottom 3 V of the old group. **E** The ratio of 3 V surface occupied by tanycytic layer revealed no differences in tanycyte territory between old groups of WT and AD mice ($n=5$). Two-way ANOVA with Bonferroni's post hoc test




Fig. 3 (See legend on previous page.)

peripheral glucose metabolic parameters (RBG and FBG) tend to be exacerbated by age, and hypothalamic cellular activation in old AD mice is limited in response to blood glucose fluctuations. Additionally, hypothalamic A β load was negatively associated with RBG in both Old-AD-Male and Old-AD-Female mice.

Extracellular deposition of A β is a primary neuropathologic hallmark in AD [37]. While A β plaques in the cortex and hippocampus researchers have been extensively investigated in AD mouse models, evaluation of hypothalamic amyloidosis is comparatively limited. In a study by Carrero et al. [38], no A β immunostaining was detected in the hypothalamus of 12-month-old male APP/PS1 mice; however, confocal imaging revealed intracellular A β immunostaining within hypothalamic neurons. Similarly, Tsui KC and colleagues provided a panoramic view of A β distribution in 9-month-old female 5xFAD mice, claiming no amyloidosis in specific hypothalamic regions such as the PVN, SCN, LH, and TuN. In their study, however, Fig. 6h showed mild A β deposition in the lateral and medial mammillary nucleus, despite the lack of detailed results description [39]. In line with this, our observations revealed abundant 6E10+ and A β ₁₋₄₂ plaques in the MM of 15-month-old APP/PS1 mice. Additionally, A β deposition in the preoptic, anterior, and tuberal region of the hypothalamus was mild in Old-AD-Female mice and minimal in Old-AD-Male mice. Among these regions, we observed that the fornix, a component of the limbic system, was particularly affected by A β deposition. Clinically, the fornix has been identified as a potential therapeutic target of AD to enhance inter-regional connectivity and improve memory function, impairment of which may stem from A β deposition [40, 41].

Studies exploring the effect of sex on AD appear to be contradictory due to variations in the ages and construction methods of AD mice utilized. For instance, a study based on non-transgenic amyloidosis mice model (involving intracerebroventricular injection of A β ₁₋₄₂) found similar alterations in long-term potentiation (LTP) and long-term depression (LTD) in both male and female groups [42]. One possible explanation is that mice used were 3–6 months old, and any sexual differences may have been too subtle to detect. Sexual dimorphism may

manifest in later stages of AD [43]. In contrast, another study described more prominent amyloid plaques in the hippocampus of female 3xTg mice compared to male 3xTg mice, with estrogen deficiency-induced PKA-CREB-MAPK (protein kinase A-cAMP response element-binding protein and p38-mitogen-activated protein kinases) signaling disorder involved [44]. Similarly, we observed higher A β loads of 6E10+ and A β ₁₋₄₂ in the hypothalamus of old AD mice, with female developing more plaques than male subsets. Sex-dependent hypothalamic neuropathology might reflect distinct compensatory mechanisms during the late stages of AD pathogenesis. In contrast, during the early stages of AD, genotype rather than sex appears to be the dominant factor in hypothalamic A β deposition, as evidenced by the presence of a few A β plaques in the mammillary region of both young male and female AD mice. However, our study does not specifically investigate the key molecular players or signaling pathways underlying sex differences in hypothalamic neuropathology.

Post-mortem examination of elderly AD patients has revealed neuronal loss in the SCN [45], LH [46] and MM [47], as well as the presence of dystrophic axons and abnormal spines in the SON and PVN [48]. Some AD transgenic mouse models replicated the neuronal loss observed in human patients. Poon CH [29] reported a significant decrease in the number of NeuN+ cells in the subiculum of 6-month-old male and female 5xFAD mouse model. Trujillo-Estrada [49] reported reduced somatostatin+ neurons in the subiculum of 4-month-old male A β PP751SwedLondon/PS1M146L mice. In our study, to objectively assess neuronal populations, we evaluated neuronal density per unit area rather than total neuronal numbers in various hypothalamic nuclei. Consequently, the density of HuCD+ neurons was minimally affected by A β cytotoxicity in this AD mouse line. Consistent with normal density, stable *Glut 3* mRNA in the AD hypothalamus indicated that the neural capacity for transporting glucose was probably retained. However, a limitation of our study is that we did not quantify functional neuronal subgroups in the hypothalamus of AD mice via fluorescence-activated cell sorting (FACS). In addition, faulty autolysosome acidification in neurons

(See figure on next page.)

Fig. 4 Systemic glucose metabolism and food intake of the young and old group. **A** The workflow displaying experimental timelines in this study. Metabolic measurements are 1 week apart from adjacent ones, allowing for animal recovery. Groups of both ages, genotypes and genders, totally 8 subsets (Young-WT-Male, Young-WT-Female, Young-AD-male, Young-AD-female, Old-WT-Male, Old-WT-Female, Old-AD-Male, Old-AD-Female), are sacrificed after 4 weeks. The schematic pictures also present processes before c-Fos analysis and RT-qPCR. Young groups: **B** Random blood glucose levels (n = 13–14). **C** 16-h Fasting blood glucose levels (n = 13–14). **D** IPGTT (n = 6). **E** Subcutaneous fat mass (n = 9). **F** Food intake during the day (n = 13–17). **G** Rebound food intake after 16-h fasting (n = 8–15). Old groups: **H** Random blood glucose levels (n = 13–14). **I** 16-h Fasting blood glucose levels (n = 13–14). **J** IPGTT (n = 6). **K** Subcutaneous fat mass (n = 9). **L** Food intake during the day (n = 13–14). **M** Rebound food intake after 16-h fasting (n = 10–13). **p < 0.01; ***p < 0.001, two-way ANOVA followed by Bonferroni's multiple comparison




Fig. 4 (See legend on previous page.)




Fig. 5 Glucose-induced cell activation of in hypothalamic metabolism-regulating nuclei of 8 subsets. **A** Images of c-Fos immunofluorescence in the young group (Young-WT-Male, Young-WT-Female, Young-AD-male, Young-AD-female). Nucleus-specific quantification of c-Fos + cells in DMH, VMH, ARH, TuN, and LH (n=5–7). A total of 19,264 c-Fos+ cells were counted. Scale bar, 500 μ m. **B**. Images of c-Fos immunofluorescence in the old group (Old-WT-Male, Old-WT-Female, Old-AD-Male, Old-AD-Female). Nucleus-specific quantification of c-Fos + cells in DMH, VMH, ARH, TuN, and LH (n=5–9). Scale bar, 500 μ m. *p < 0.05; **p < 0.01, two-way ANOVA followed by Bonferroni's multiple comparison




Fig. 6 Relative mRNA expression of Glut1 (A, B), Glut3 (C, D) in the hypothalamus of both young and old male and female WT and AD groups mice. Pearson correlation of several parameters in Old-AD-Male and Old-AD-Female groups (E, F). The correlation coefficient was listed on the left and below side of each matrix. * $p < 0.05$; ** $p < 0.01$

of AD mouse models leads to intracellular autophagic accumulation of Aβ peptides [50]. Therefore, it would be interesting to explore early functional changes in neuronal lysosomes in the hypothalamus of APP/PS1 mice.

Glial activation is a complex neuropathology in AD [51]. As a recognized cellular marker of neuroinflammation, microgliosis is predominantly localized to the core of Aβ deposits [52]. Although *Tnf-α* and *Ikkβ* mRNA levels in our study indicate no significantly elevated neuroinflammation in the overall AD hypothalamus, we consider it to be an integrated consequence of hypothalamus-residing cells (including neurons, microglia, astrocytes, and others). The percentage of IBA1-positive area in the MM was greater in Old-AD-Female mice than in Old-AD-Male mice, corresponding to the 6E10+and Aβ₁₋₄₂+amyloid load. Since severe microgliosis was detected in the LH and MM but not in other

hypothalamic nuclei, such localized inflammation might be too subtle to detect. In Pearson correlation analyses of aged APP/PS1 mice, we found no significant correlations between hypothalamic IBA1% areas and Aβ deposition. One potential reason is that, to remain consistent with the measurement standard of Aβ load, we analyzed IBA1-covered areas of the total hypothalamus (beyond MM). Another reason could be the presence of complicated microglial subgroups in various hypothalamic nuclei, which may exhibit different IBA1 immunoreactivity. Tools targeting proinflammatory and anti-inflammatory microglial subtypes with high specificity may help interpret our findings. GLUT1 predominantly facilitates glucose uptake in microglia [53] and mediates microglial proinflammatory activation [54]. In our study, *Glut 1* mRNA expression was decreased in Young-AD-Female mice and increased in Old-AD-Female mice,

implying variable microglial glucose metabolism in the AD hypothalamus.

Tanycytes have been speculated to be the missing link between type 2 diabetes and AD and are therefore considered for targeted gene-editing and stem cell-based patient-specific therapies for AD [55, 56]. To the best of our knowledge, our study is the first to dissect tanycytes in a mouse model of AD. We observed no atrophic tanycytic territory and honeycombed ZO-1 pattern in AD mice, implying a normal blood–cerebrospinal fluid barrier (BCSFB) constituted by the tanycyte population. Due to technical limitations, we did not reveal ultrastructural connections with organelles in tanycytes, such as mitochondria and lysosomes [57]. Functionally, hypothalamus-controlled downstream metabolic effects are partially mediated by tanycytes [58, 59]. Activation of tanycytes through the arcuate neuronal network leads to acute hyperphagia [60], and they are proven essential for rodents to initiate a meal after fasting [61]. With high functional heterogeneous [62], a subpopulation of tanycytes expresses key taste transduction genes and regulate glucose homeostasis [63]. Thus, it is highly possible that tanycytes in AD mice retain the ability to sustain normal food intake, unaffected by age and sex.

Hypothalamic-based metabolic disorders are another critical pathological feature in AD [64, 65], often preceding amyloid plaques [66, 67]. Negative energy balance (decreased body weight, food intake, and energy expenditure) and metabolic dysfunctions (insulin, leptin, ghrelin) have been reported in 6-month-old male and female 5xFAD mice [68]. In our study, however, no significant difference was found in feeding behaviors of all animal groups, suggesting negligible impact from sex, age, and AD pathology. Expression of *c-Fos* reveals a limited response of AD hypothalamic feed-related nuclei when challenged with raised blood glucose. Notably, glucose-induced *c-Fos*+ cells were more dramatically reduced in Old-AD-Male compared to Old-AD-Female mice, displaying sex-dependent patterns. We infer that in Old-AD-Male mice, hypothalamic neurons transition from activated states to resting states to adapt to rapidly rising glycemia. In contrast, neurons in Old-AD-Female mice fail to complete this transition, likely due to higher A β deposition. In line with our results, other studies have reported that alterations in hypothalamic glucose sensing and utilization are mild in 2–3-month-old APP+ mice [69], and 11-month-old male APP/PS1 mice fed standard chow showed normal FBG and glucose tolerance compared with WT mice [70].

Additionally, we showed significantly different RGB and FBG in aged AD male and female mice. Unexpectedly, such sex-based difference also existed in

Old-WT-Male and Old-WT-Female mice (but not in Young-Female-WT and Young-Male-WT mice). Other studies have reported that 14-month-old male C57BL/6 mice had higher baseline blood glucose than female following glucose administration [71], suggesting sex-specific impairments in blood glucose regulation [72]. The underlying reason might be that age combined with sex (or age interacting with sex) has a greater impact than sex or AD genotype alone, causing a statistical difference in glucose metabolic parameters in old WT groups. By contrast, FBG showed a decreasing trend in Young-WT-Female compared with Young-WT-Male mice (and statistically differed between Young-AD-Female and Young-Male-AD mice), and RGB was comparable across all four young subsets, further emphasizing the significant influence of age on metabolism. We thus infer that sex differences in systemic glycemia seem to be exacerbated by age but are unlikely to be influenced by AD status. Furthermore, Pearson correlation analysis revealed that hypothalamic A β load was negatively correlated with RGB in both old AD male and female mice. In young AD male and female mice, a few A β plaques appeared in the mammillary region of the hypothalamus, implying a potential link between blood glucose metabolism and hypothalamic AD pathology. Notably, more studies are warranted to confirm this link in the early pathological stages.

Limitations of this study also include the lack of soluble A β examination in the blood sample from both male and female AD mice. Soluble A β proteins are promising early diagnostic biomarkers of AD, as their imbalance in production and clearance across the blood–brain barrier has been implicated [73]. Moreover, we did not directly measure glucose levels in the interstitial fluid of the hypothalamic parenchyma and compare them with peripheral glucose levels. It would be fascinating to clarify whether the AD hypothalamus fails in glucose sensation, and transportation, or rather experiences a decline in energy demand. We primarily explored blood glucose levels in our metabolic study and did not investigate other metabolic parameters, such as insulin, leptin, ghrelin, which limits our findings from being generalized to integrated metabolic disturbances. Functionally, resting-state functional connectivity of the hypothalamic precuneus/posterior cingulate cortex were diminished in AD patients [74]. This suggests that in addition to hypothalamic histopathology changes, signaling exchanges between the hypothalamus and other brain regions may also be impaired in AD. Investigating key and vulnerable monosynaptic projections from other brain regions to the integrative hypothalamus, which mediate glucose disorders, would be of great interest in the future research.




Fig. 7 Schematic diagram showing sexual differences in the AD mice model. The pictures reflected lower glycemia in Old-AD-Female mice, coupled with heavier A β burden, elevated *Glut1* expression and activated microglia

Conclusions

In summary (Fig. 7), we have demonstrated more extensive hypothalamic amyloid plaques in females than males in the late stage of this AD mouse model. The MM exhibits the earliest and heaviest A β load within the hypothalamus, accompanied by microgliosis. Sex-specific systemic glucose metabolism (RBG and FBG) seems to be exacerbated by age, and *c-Fos* expression in hypothalamic nuclei regulating feeding is limited in the old AD groups of both sexes, indicating impaired glucose metabolic adaptation. These findings underscore the importance of considering sex-specific hypothalamic amyloidosis and age-related sex differences in blood glucose metabolism.

Abbreviations

AD	Alzheimer's disease
A β	Amyloid beta
α 7nAChR	α 7 nicotinic acetylcholine receptor
3 V	Third ventricle
WT	Wild-type
APP	Amyloid precursor protein
PS1	Presenilin 1

PBS	Phosphate-buffered saline
i.p.	Intraperitoneal injection
ROI	Region of interest
AC	Anterior commissure
MPO	Medial preoptic nucleus
LPO	Lateral preoptic nucleus
PVN	Paraventricular nucleus
AHC	Anterior hypothalamic nucleus
SCN	Suprachiasmatic nucleus
SON	Supraoptic nucleus
LH	Lateral hypothalamus
DMH	Dorsal medial nucleus
VMH	Ventral medial nucleus
ARH	Arcuate nucleus
TuN	Tuberal nucleus
PH	Posterior hypothalamic nucleus
PKM2	Pyruvate kinase M2
GFAP	Glial fibrillary acidic protein
IL-1 β	Interleukin-1 β
SuM	Supramammillary nucleus
MM	Mammillary bodies
RBG	Random blood glucose
FBG	Fasting blood glucose
IPGTT	Intraperitoneal glucose tolerance test
RT-qPCR	Real-time quantitative PCR
Ct	Cycle threshold

SEM	Standard error of the mean
ANOVA	Analysis of variance
<i>Ikkbβ</i>	An inhibitor of nuclear factor kappa-B kinase subunit beta
BBB	Blood–brain barrier
GLUT1	Glucose transporter 1
GLUT3	Glucose transporter 3
LTP	Long-term potentiation
LTD	Long-term depression
PKA-CREB-MAPK	Protein kinase A-cAMP response element-binding protein and p38–mitogen-activated protein kinases
FACS	Fluorescence-activated cell sorting
BCSFB	Blood–cerebrospinal fluid barrier

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13578-024-01295-5>.

Additional file 1: Fig. S1 Representative confocal images of amyloid plaques in the Old-AD-Male and Old-AD-Female subsets. 6E10+ and $\text{A}\beta$ 1–42+ plaques are observed in the fornix (A), mammillary bodies (B), but not in the suprachiasmatic nucleus. Scale bar, 50 μm . Fig. S2 Analysis of amyloid plaques in hypothalamic subdivisions of the young group. Representative images of 6E10 and $\text{A}\beta$ 1–42 co-staining in hypothalamic pre-optic, anterior (A), tuberal, and mammillary (B) regions of Young-AD-Male and Young-AD-Female subsets. Fig. S3 Neurons in various hypothalamic nuclei and neuroinflammation elements. A Images of HuCD immunofluorescence in the young group. Scale bar, 200 μm . Quantification of the number of HuCD+ neurons in various nuclei. B, C Tnf- α and *Ikkb β* mRNA expression in the young group were evaluated. D Images of HuCD immunofluorescence in the young group. Scale bar, 200 μm . Quantification of the number of HuCD+ neurons in various nuclei. E, F Tnf- α and *Ikkb β* mRNA expression in the young group were evaluated. Fig. S4 Staining of IBA1 and GFAP in various hypothalamic nuclei. A Representative image of IBA1 staining in mammillary bodies of the young group. B Percentage of ROI occupied by IBA1-positive area ($n = 3$). Representative image of GFAP staining in mammillary bodies of the young group (c) and old group(d). * $p < 0.05$, two-way ANOVA followed by Bonferroni's multiple comparison. Fig. S5 Vimentin-positive tanycytes distribute from zone 1 to zone 4 in the young group. Pattern of tight junction protein ZO-1 (red) is honeycombed in bottom 3V of the young group

Acknowledgements

We thank Fanny Langlet for kindly providing the schematic of tanycytes, Yaojuan Shi for technical assistance in breeding the mice, Xinyu Chen for technical advice on confocal microscopy, Yinjun Ma for metabolic studies and Wentong Hong for guidance of statistics.

Author contributions

S.Q. and L.C. conceived the project. S.Q. and G.Q. designed experiments. G.Q. performed most of the experiments. H.T., P.G. and Y.L., assisted with the experiments. C.H. J.H. and S.K. assisted with data analysis. G.Q. and S.Q. wrote the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (31871477, 32170971, and 81528006), the Natural Science Foundation of Shanghai (18ZR1403800), and the National Key Basic Research Program of China (973 Program, No.2014CB965001) to S.Q., the Qing-Feng scholar research foundation of Shanghai Medical College, Fudan University (QF2212) to H.T.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

All animal experiments were performed according to the policies and ethical regulations established by the Animal Care and Use Committee of Shanghai Medical College of Fudan University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 17 May 2024 Accepted: 21 August 2024

Published online: 13 September 2024

References

- Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. *Cell*. 2019;179(2):312–39.
- Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. *Nat Rev Dis Primers*. 2021;7(1):33.
- Usenovic M, Niroomand S, Drolet RE, Yao L, Gaspar RC, Hatcher NG, Schachter J, Renger JJ, Parmentier-Batteur S. Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. *J Neurosci*. 2015;35(42):14234–50.
- Finder VH, Glockshuber R. Amyloid-beta aggregation. *Neurodegener Dis*. 2007;4(1):13–27.
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and down syndrome. *Proc Natl Acad Sci U S A*. 1985;82(12):4245–9.
- Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J Neurosci*. 2006;26(40):10129–40.
- Fong H, Zheng J, Kurrasch D. The structural and functional complexity of the integrative hypothalamus. *Science*. 2023;382(6669):388–94.
- 2023 Alzheimer's Disease Facts and Figures. *Alzheimers Dement*. 2023;19(4):1598–1695.
- Fancy NN, Smith AM, Caramello A, Tsartsalis S, Davey K, Muirhead RCJ, McGarry A, Jenkyns MH, Schneegans E, Chau V, et al. Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics. *Acta Neuropathol*. 2024;147(1):78.
- Henningfield CM, Soni N, Lee RW, Sharma R, Cleland JL, Green KN. Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer's disease mouse model. *Alzheimers Res Ther*. 2024;16(1):101.
- Pan RY, He L, Zhang J, Liu X, Liao Y, Gao J, Liao Y, Yan Y, Li Q, Zhou X, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease. *Cell Metab*. 2022;34(4):634–648 e636.
- Fontana IC, Kumar A, Nordberg A. The role of astrocytic alpha7 nicotinic acetylcholine receptors in Alzheimer disease. *Nat Rev Neurol*. 2023;19(5):278–88.
- Garcia-Caceres C, Bolland E, Prevot V, Luquet S, Woods SC, Koch M, Horvath TL, Yi CX, Chowen JA, Verkhatsky A, et al. Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism. *Nat Neurosci*. 2019;22(1):7–14.
- Mullier A, Bouret SG, Prevot V, Dehouck B. Differential distribution of tight junction proteins suggests a role for tanycytes in blood-hypothalamus barrier regulation in the adult mouse brain. *J Comp Neurol*. 2010;518(7):943–62.
- Langlet F, Levin BE, Luquet S, Mazzone M, Messina A, Dunn-Meynell AA, Bolland E, Lacombe A, Mazur D, Carmeliet P, et al. Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic

- signals to the arcuate nucleus in response to fasting. *Cell Metab.* 2013;17(4):607–17.
16. Jais A, Bruning JC. Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus. *Endocr Rev.* 2022;43(2):314–28.
 17. Duquenne M, Folgueira C, Bourouh C, Millet M, Silva A, Clasadonte J, Imbernon M, Fernandois D, Martinez-Corral I, Kusumakshi S, et al. Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function. *Nat Metab.* 2021;3(8):1071–90.
 18. Yoo S, Cha D, Kim S, Jiang L, Cooke P, Adebisin M, Wolfe A, Riddle R, Aja S, Blackshaw S. Tanycyte ablation in the arcuate nucleus and median eminence increases obesity susceptibility by increasing body fat content in male mice. *Glia.* 2020;68(10):1987–2000.
 19. Mu WH, Li S, Xu JK, Guo XZ, Wu HD, Chen ZH, Qiao LY, Helfer G, Lu FL, Liu C, et al. Hypothalamic Rax(+) tanycytes contribute to tissue repair and tumorigenesis upon oncogene activation in mice. *Nat Commun.* 2021. <https://doi.org/10.1038/s41467-021-22640-z>.
 20. Liu X, Wang W, Chen HL, Zhang HY, Zhang NX. Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice. *Acta Pharmacol Sin.* 2019;40(10):1259–68.
 21. Knight EM, Ruiz HH, Kim SH, Harte JC, Hsieh W, Glabe C, Klein WL, Attie AD, Buettner C, Ehrlich ME, et al. Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1. *Acta Neuropathol Commun.* 2016;4:16.
 22. Zheng H, Zhou Q, Du Y, Li C, Xu PT, Lin L, Xiao J, Gao HC. The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. *Bba-Mol Basis Dis.* 2018;1864(1):263–73.
 23. Robison LS, Gannon OJ, Salinero AE, Abi-Ghanem C, Kelly RD, Riccio DA, Mansour FM, Zuloaga KL. Sex differences in metabolic phenotype and hypothalamic inflammation in the 3xTg-AD mouse model of Alzheimer's disease. *Biol Sex Differ.* 2023;14(1):51.
 24. Freire-Regatillo A, Diaz-Pacheco S, Frago LM, Arevalo MA, Argente J, Garcia-Segura LM, de Ceballos ML, Chowen JA. Sex differences in hypothalamic changes and the metabolic response of TgAPP mice to a high fat diet. *Front Neuroanat.* 2022;16:910477.
 25. Robison LS, Gannon OJ, Thomas MA, Salinero AE, Abi-Ghanem C, Poitelon Y, Belin S, Zuloaga KL. Role of sex and high-fat diet in metabolic and hypothalamic disturbances in the 3xTg-AD mouse model of Alzheimer's disease. *J Neuroinflammation.* 2020;17(1):285.
 26. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep.* 2006;7(9):940–6.
 27. Li KY, Gong PF, Li JT, Xu NJ, Qin S. Morphological and molecular alterations of reactive astrocytes without proliferation in cerebral cortex of an APP/PS1 transgenic mouse model and Alzheimer's patients. *Glia.* 2020;68(11):2361–76.
 28. Hong W, Gong P, Pan X, Liu Y, Qi G, Qi C, Qin S. Kruppel-like factor 7 deficiency disrupts corpus callosum development and neuronal migration in the developing mouse cerebral cortex. *Brain Pathol.* 2023;33(5):e13186.
 29. Poon CH, Wong STN, Roy J, Wang Y, Chan HWH, Steinbusch H, Blokland A, Temel Y, Aquili L, Lim LW. Sex differences between neuronal loss and the early onset of amyloid deposits and behavioral consequences in 5xFAD transgenic mouse as a model for Alzheimer's disease. *Cells-Basel.* 2023;12(5):780.
 30. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame TM, Ramos JMP, Cahalan L, et al. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. *Nat Neurosci.* 2024;5:335.
 31. Lopez-Gamero AJ, Martinez F, Salazar K, Cifuentes M, Nualart F. Brain glucose-sensing mechanism and energy homeostasis. *Mol Neurobiol.* 2019;56(2):769–96.
 32. Pasquettaz R, Kolotuev I, Rohrbach A, Gouelle C, Pellerin L, Langlet F. Peculiar protrusions along tanycyte processes face diverse neural and nonneural cell types in the hypothalamic parenchyma. *J Comp Neurol.* 2021;529(3):553–75.
 33. Lochhead JJ, Yang J, Ronaldson PT, Davis TP. Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders. *Front Physiol.* 2020;11:914.
 34. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease—insights from amyloid-beta metabolism beyond the brain. *Nat Rev Neurol.* 2017;13(11):703.
 35. Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, Sengillo JD, Hillman S, Kong P, Nelson AR, et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. *Nat Neurosci.* 2015;18(4):521–30.
 36. Peng W, Tan C, Mo L, Jiang J, Zhou W, Du J, Zhou X, Liu X, Chen L. Glucose transporter 3 in neuronal glucose metabolism: health and diseases. *Metabolism.* 2021;123:154869.
 37. Poon CH, Wang Y, Fung ML, Zhang C, Lim LW. Rodent models of amyloid-beta feature of Alzheimer's disease: development and potential treatment implications. *Aging Dis.* 2020;11(5):1235–59.
 38. Carrero L, Antequera D, Alcalde I, Megias D, Figueiro-Silva J, Merayo-Lloves J, Municio C, Carro E. Disturbed circadian rhythm and retinal degeneration in a mouse model of Alzheimer's disease. *Acta Neuropathol Commun.* 2023;11(1):55.
 39. Tsui KC, Roy J, Chau SC, Wong KH, Shi L, Poon CH, Wang Y, Strelakova T, Aquili L, Chang RC, et al. Distribution and inter-regional relationship of amyloid-beta plaque deposition in a 5xFAD mouse model of Alzheimer's disease. *Front Aging Neurosci.* 2022;14:964336.
 40. Senova S, Fomenko A, Gondard E, Lozano AM. Anatomy and function of the fornix in the context of its potential as a therapeutic target. *J Neurol Neurosurg Psychiatry.* 2020;91(5):547–59.
 41. Li R, Zhang C, Rao Y, Yuan TF. Deep brain stimulation of fornix for memory improvement in Alzheimer's disease: a critical review. *Ageing Res Rev.* 2022;79:101668.
 42. Jimenez-Herrera R, Contreras A, Djebari S, Mulero-Franco J, Iborra-Lazaro G, Jeremic D, Navarro-Lopez J, Jimenez-Diaz L. Systematic characterization of a non-transgenic Abeta(1–42) amyloidosis model: synaptic plasticity and memory deficits in female and male mice. *Biol Sex Differ.* 2023;14(1):59.
 43. Sauty B, Durrleman S. Impact of sex and APOE-epsilon4 genotype on patterns of regional brain atrophy in Alzheimer's disease and healthy aging. *Front Neurol.* 2023;14:1161527.
 44. Yang JT, Wang ZJ, Cai HY, Yuan L, Hu MM, Wu MN, Qi JS. Sex differences in neuropathology and cognitive behavior in APP/PS1/tau triple-transgenic mouse model of Alzheimer's disease. *Neurosci Bull.* 2018;34(5):736–46.
 45. Harper DG, Stopa EG, Kuo-Leblanc V, McKee AC, Asayama K, Volicer L, Kowall N, Satlin A. Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. *Brain.* 2008;131(Pt 6):1609–17.
 46. Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Alzheimer's disease. *Neurobiol Aging.* 2012;33(8):1642–50.
 47. Baloyannis SJ, Mavroudis I, Baloyannis IS, Costa VG. Mammillary bodies in Alzheimer's disease: a golgi and electron microscope study. *Am J Alzheimers Dis Other Dement.* 2016;31(3):247–56.
 48. Baloyannis SJ, Mavroudis I, Mitilneos D, Baloyannis IS, Costa VG. The hypothalamus in Alzheimer's disease: a golgi and electron microscope study. *Am J Alzheimers Dis Other Dement.* 2015;30(5):478–87.
 49. Trujillo-Estrada L, Davila JC, Sanchez-Mejias E, Sanchez-Varo R, Gomez-Arboledas A, Vizuete M, Vitorica J, Gutierrez A. Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-beta accumulation in AbetaPP/PS1 Alzheimer's disease mice subiculum. *J Alzheimers Dis.* 2014;42(2):521–41.
 50. Lee JH, Yang DS, Goulbourne CN, Im E, Stavrides P, Pensalfini A, Chan H, Bouchet-Marquis C, Bleiwas C, Berg MJ, et al. Faulty autolysosomal acidification in Alzheimer's disease mouse models induces autophagic build-up of Abeta in neurons, yielding senile plaques. *Nat Neurosci.* 2022;25(6):688–701.
 51. Uddin MS, Lim LW. Glial cells in Alzheimer's disease: from neuropathological changes to therapeutic implications. *Ageing Res Rev.* 2022;78:101622.
 52. Zhang J, Wu N, Wang S, Yao Z, Xiao F, Lu J, Chen B. Neuronal loss and microgliosis are restricted to the core of Abeta deposits in mouse models of Alzheimer's disease. *Aging Cell.* 2021;20(6):e13380.
 53. Wang L, Pavlou S, Du X, Bhuckory M, Xu H, Chen M. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. *Mol Neurodegener.* 2019;14(1):2.

54. Wang X, Wu Y, Tian Y, Hu H, Zhao Y, Xue B, Sun Z, Wei A, Xie F, Qian LJ. GLUT1-mediated microglial proinflammatory activation contributes to the development of stress-induced spatial learning and memory dysfunction in mice. *Cell Biosci.* 2024;14(1):48.
55. Raikwar SP, Bhagavan SM, Ramaswamy SB, Thangavel R, Dubova I, Selvakumar GP, Ahmed ME, Kempuraj D, Zaheer S, Iyer S, et al. Are tanycytes the missing link between type 2 diabetes and Alzheimer's disease? *Mol Neurobiol.* 2019;56(2):833–43.
56. Raikwar SP, Thangavel R, Dubova I, Ahmed ME, Selvakumar GP, Kempuraj D, Zaheer S, Iyer S, Zaheer A. Neuro-immuno-gene-and genome-editing-therapy for Alzheimer's disease: are we there yet? *J Alzheimers Dis.* 2018;65(2):321–44.
57. Rodriguez E, Guerra M, Peruzzo B, Blazquez JL. Tanycytes: a rich morphological history to underpin future molecular and physiological investigations. *J Neuroendocrinol.* 2019. <https://doi.org/10.1111/jne.12690>.
58. Benevento M, Alpar A, Gundacker A, Afjehi L, Balueva K, Hevesi Z, Hanics J, Rehman S, Pollak DD, Lubec G, et al. A brainstem-hypothalamus neuronal circuit reduces feeding upon heat exposure. *Nature.* 2024;628(8009):826–34.
59. Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, Denis RGP, Chao DHM, Rasika S, Staels B, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. *Cell Metab.* 2022;34(7):1054–1063 e1057.
60. Bolborea M, Pollatzek E, Benford H, Sotelo-Hitschfeld T, Dale N. Hypothalamic tanycytes generate acute hyperphagia through activation of the arcuate neuronal network. *Proc Natl Acad Sci U S A.* 2020;117(25):14473–81.
61. Rohrbach A, Caron E, Dali R, Brunner M, Pasquettaz R, Kolotuev I, Santoni F, Thorens B, Langlet F. Ablation of glucokinase-expressing tanycytes impacts energy balance and increases adiposity in mice. *Mol Metab.* 2021;53:101311.
62. Sullivan AI, Potthoff MJ, Flippo KH. Tany-Seq: integrated analysis of the mouse tanycyte transcriptome. *Cells-Basel.* 2022;11(9):1565.
63. Yu Q, Gamayun I, Wartenberg P, Zhang Q, Qiao S, Kusumakshi S, Candlish S, Gotz V, Wen S, Das D, et al. Bitter taste cells in the ventricular walls of the murine brain regulate glucose homeostasis. *Nat Commun.* 2023;14(1):1588.
64. Pan X, Nasaruddin MB, Elliott CT, McGuinness B, Passmore AP, Kehoe PG, Holscher C, McClean PL, Graham SF, Green BD. Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. *Neurobiol Aging.* 2016;38:151–63.
65. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target of pathology. *Cell Metab.* 2015;22(5):761–76.
66. Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, Rhim HS, Choi CB, Kim HY, Lee CU, Choe BY. Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS. *Behav Brain Res.* 2010;211(1):125–31.
67. de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. *Biochem Pharmacol.* 2014;88(4):548–59.
68. Lopez-Gambero AJ, Rosell-Valle C, Medina-Vera D, Navarro JA, Vargas A, Rivera P, Sanjuan C, Rodriguez de Fonseca F, Suarez J. A negative energy balance is associated with metabolic dysfunctions in the hypothalamus of a humanized preclinical model of Alzheimer's disease, the 5XFAD mouse. *Int J Mol Sci.* 2021;22(10):5365.
69. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. *Neurobiol Dis.* 2002;9(1):61–8.
70. Ruiz HH, Chi T, Shin AC, Lindtner C, Hsieh W, Ehrlich M, Gandy S, Buettner C. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer's disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. *Alzheimers Dement.* 2016;12(8):851–61.
71. Dockman RL, Carpenter JM, Diaz AN, Benbow RA, Filipov NM. Sex differences in behavior, response to LPS, and glucose homeostasis in middle-aged mice. *Behav Brain Res.* 2022;418:113628.
72. de Souza GO, Wasinski F, Donato J Jr. Characterization of the metabolic differences between male and female C57BL/6 mice. *Life Sci.* 2022;301:120636.
73. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease—insights from amyloid-beta metabolism beyond the brain. *Nat Rev Neurol.* 2017;13(10):612–23.
74. Chaudhary S, Zhornitsky S, Chao HH, van Dyck CH, Li CR. Hypothalamic functional connectivity and apathy in people with Alzheimer's disease and cognitively normal healthy controls. *J Alzheimers Dis.* 2022;90(4):1615–28.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.